Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Study Overview
=================
Brief Summary
-----------------
This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute hepatitis C virus (HCV) infection.

Detailed Description
-----------------
This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with SOF/VEL FDC for 8 weeks in patients with acute HCV infection as measured by the proportion of subjects with sustained viral response (undetectable HCV RNA) 12 weeks after stop of therapy.

Official Title
-----------------
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study

Conditions
-----------------
Hepatitis C, Acute Hepatitis C

Intervention / Treatment
-----------------
* Drug: Sofosbuvir and Velpatasvir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide written informed consent Male or female, age > 18 years HCV RNA > 10^3 IU/mL at screening Confirmation of acute HCV infection documented by either: Documented seroconversion to HCV antibody (anti-HCV) positivity within the 4 months preceding screening Documented conversion to HCV RNA positivity within the 4 months preceding screening or known or suspected exposure to HCV within the 4 months preceding screening with 10 times elevated serum ALT level at screening or 4 month preceding screening without evidence of confounding liver disorders Body mass index (BMI) ≥18 kg/m2 Subjects must have the following laboratory parameters at screening: INR ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR HbA1c ≤ 10% Creatinine clearance (CLcr) ≥ 30 mL/min, as calculated by the Cockcroft-Gault equation (using actual body weight) A negative serum pregnancy test is required for female subjects (unless surgically sterile or women ≥ 54 years of age with cessation for 24 ≥ months of previously occurring menses). Complete abstinence from intercourse. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not permitted. Or Consistent and correct use of 1 of the following methods of birth control listed below, in addition to a male partner who correctly uses a condom, from the date of Screening until the end of follow up: intrauterine device (IUD) with a failure rate of < 1% per year female barrier method: cervical cap or diaphragm with spermicidal agent tubal sterilization vasectomy in male partner hormone-containing contraceptive: implants of levonorgestrel injectable progesterone oral contraceptives (either combined or progesterone only) contraceptive vaginal ring transdermal contraceptive patch Subject must be able to comply with the dosing instructions for study drug administration and be able to complete the study schedule of assessments Exclusion Criteria: Subject has been treated with any investigational drug or device within 42 days of the Screening visit Co-Infection with HIV Clinically-significant illness (other than HCV) or any other major medical disorder that, in the opinion of the investigator, may interfere with subject treatment, assessment or compliance with the protocol. Solid organ transplantation Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug (for example, gastric bypass or severe ulcerative colitis). Clinical signs of hepatic decompensation (i.e., clinical ascites, encephalopathy or variceal hemorrhage). Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy. Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their psychiatric illness within the last 2 years. Subjects with psychiatric illness that is well-controlled on a stable treatment regimen for at least 12 months prior to screening or has not required medication in the last 12 months may be included. Significant drug allergy (such as anaphylaxis or hepatotoxicity). Pregnant or nursing female Clinically-relevant drug or alcohol abuse that significantly impairs patient compliance. Uncontrolled users of intravenous drugs will not be permitted to enroll in the study. Clinical relevant (not controlled) liver disease of a non-HCV etiology (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, Wilson's disease, α1 antitrypsin deficiency, cholangitis) Use of any prohibited concomitant medications within 21 days before the Baseline/Day 1 visit. The use of amiodarone is prohibited from 60 days prior to Day 1 through the end of treatment; Known hypersensitivity to SOF/VEL or formulation excipients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Prospective, open-label, single-arm multicenter, phase II pilot trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sofosbuvir and Velpatasvir<br>SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks | Drug: Sofosbuvir and Velpatasvir<br>* All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.<br>* Other names: Epclusa 400 mg/100 mg film-coated tablets;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects with sustained virological response (undetectable HCV RNA) 12 weeks after discontinuation of therapy | Measured by the portion of subjects with sustained virological response (undetectable HCV RNA) | 12 weeks after discontinuation of therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean HCV RNA viral load at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after stop of therapy | Measured by mean HCV RNA viral load | at baseline, after 2 weeks, 4 weeks and 8 weeks of therapy, and 12 weeks after stop of therapy | 
| Proportion of subjects who reached ALT normalization (ALT < ULN) after 8 weeks of therapy and 12 weeks after discontinuation of therapy | Measured by the proportion of subjects who reached ALT normalization (ALT < ULN) | after 8 weeks of therapy, and 12 weeks after discontinuation of therapy | 
| Assessment of frequency and severity of adverse events (AEs) | Collection of all AEs | through study completion, an average of 20 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute hepatitis C virus (HCV) infection